

Important Health Notice

April 23, 2009

Volume 6, Issue 1

Page 1 of 2

Information for Healthcare Professionals Clusters of Severe Respiratory Illness in Mexico

The Ministry of Health and Long Term Care and the Ontario Agency for Health Protection and Promotion were contacted on April 20th by the Public Health Agency of Canada (PHAC) regarding a number of individuals with severe respiratory illness (SRI) occurring in various locations of south and central Mexico.

Epidemiology Update from PHAC:

Two clusters have been identified, one in Mexico City and one San Luis Potosi. As of yesterday, 23 hospitals in Mexico City have reported 120 SRI cases including 13 deaths. San Luis Potosi (central Mexico) has reported 14 SRI cases including 4 deaths. Most cases have occurred in previously healthy young adults aged 25-44 years old. In addition, 1 death has been reported in Oaxaca (southern Mexico) and 2 deaths reported in Baja California Norte (bordering California, USA). Five healthcare workers have been identified in the clusters.

The clinical symptoms include high fever, headache, ocular pain, shortness of breath and extreme fatigue. Rapid progression of symptoms to severe respiratory distress occurred in about 5 days. High proportion requiring mechanical ventilation reported (exact percentage unknown). Case-fatality rate has ranged from 11 to 29% based on Mexico City and San Luis Potosi data.

The same pathogen has not been identified in all cases. To date influenza A/H1N1 and B, and one parainfluenza strain have been detected. For many cases, no pathogen has yet been identified. The National Microbiology Laboratory has received 51 clinical samples from Mexico on April 22, and will be testing them for a range of pathogens. The results of the lab testing is expected shortly.

Advice to healthcare providers

Severe Respiratory Illness (SRI) and Febrile Respiratory Illness (FRI) screening in Emergency Departments:

Emergency Departments are to use the existing Sample Case Finding/Surveillance Form in the PIDAC FRI document (attached and available at http://www.health.gov.on.ca/english/providers/program/infectious/diseases/best_prac/bp_fri_080406.pdf) with the following modifications:

- 1) In (iii), the relevant travel history question is: "Have you traveled within the last **10** days to **Mexico**?" It is important that a travel history be obtained in all patients with FRI and SRI.
- 2) Cases who meet the definition of SRI who have a travel history from Mexico in the past 10 days should be treated in droplet/contact precautions in a single room. In addition, healthcare providers should wear properly fit tested N-95 respirators for direct care of these patients. This change has been made because a pathogen has not yet been identified and because of the high mortality rate being reported at this early stage. These precautions only apply to this situation; all other healthcare providers not providing direct care to these patients only need to follow Routine Practices. As new information becomes available, this recommendation will be reviewed.

Patients with FRI who do not meet the definition of SRI but have a Mexico travel history and who do not require admission, may be sent home. There is **no** requirement for isolation at this time. There is **no** requirement to quarantine contacts of cases at this time.

Laboratory Testing:

Cases which fit the above SRI definition should have the following specimens collected for testing at PHL-Toronto:

- Nasopharyngeal swab in viral transport medium (viral culture)
- Bronchoalveolar lavage specimen if available (sterile container for viral culture)
- Throat swab in Multitrans™ transport media (*Mycoplasma/Chlamydomphila pneumoniae* pcr)
- Blood in EDTA (purple top)
- Blood in clotted tube (red top)
- Urine for *Legionella* antigen
- Other investigations such as blood cultures should be done locally
- Please write "SRI-High Priority: Attention Dr. Gubbay" on the requisition form.
- Submit the Public Health Agency of Canada (PHAC) SRI report form, available at:

http://www.phac-aspc.gc.ca/eri-ire/pdf/03-SRI-Report-Form_e.pdf

Specimens should be transported to the laboratory at 4°C. Please contact the medical microbiologist on-call prior to sending specimens to discuss whether other specimens should be collected and method of transportation. Phone:

1-800 640-7221, or after hours 416-605-3113 (Duty Officer).

Laboratory testing is not currently recommended for persons who have recently returned from Mexico with upper respiratory tract symptoms/FRI but do not have SRI.

Treatment of SRI cases:

There are no specific treatment recommendations for FRI or SRI cases with a Mexico travel history. In cases where influenza has been diagnosed, it is recommended clinicians follow the influenza treatment guidelines issued by the BC Centre for Disease Control (attached)

Case reporting to local public health

The MOHLTC case definition for SRI (dated April 23, 2009) is provided. Patients fitting this case definition are to be reported to the local health unit.

(original signed by)

Dr. David Williams
Acting Chief Medical Officer of Health

(original signed by)

Phil Graham
Interim Director, Emergency Management Unit

Appendix 2: Sample Case Finding/Surveillance Form

Case Finding/Surveillance Protocol for Febrile Respiratory Illness (Questionnaire)

- (i) Do you have new/worse cough or shortness of breath?
If 'no', stop here (no further questions)
If 'yes', continue with next question
- (ii) Are you feeling feverish*, or have you had shakes or chills in the last 24 hours?
If 'no', take temperature; if >38 C, continue with next questions, otherwise stop (no further questions)
If 'yes', take temperature and continue with next questions

*NOTE: Some people, such as the elderly and people, who are immunocompromised, may not develop a fever.

If the answer to both questions (i) and (ii) is 'yes', or the answer to question (i) is 'yes' and the recorded temperature is >38C, Initiate droplet precautions, and notify Infection Prevention and Control

- (iii) Is any of the following true?
Have you traveled within the last 10 days to Mexico?
Have you had contact in the last 10 days with a sick person who has traveled to Mexico?

Infection Prevention and Control should notify public health by phone when: case has a positive travel history and/or there is a possible cluster/outbreak

**BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL (BCCDC):
INTERIM OPTIONS FOR CLINICIANS CONSIDERING INFLUENZA ANTIVIRALS
IN THE CONTEXT OF CHANGING PATTERNS OF RESISTANCE, 2008-09 SEASON**

These interim guidelines dated February 10, 2009 are based on evolving knowledge and up-to-date surveillance data for the 2008-09 influenza season, which suggest a high rate of oseltamivir resistance in A/H1N1 viruses and a continued high rate of amantadine resistance in A/H3N2 viruses. Health care providers considering the use of antivirals should consult surveillance updates to stay informed about influenza activity and antiviral resistance patterns in their area. The appropriate choice of antiviral options may change. Influenza antivirals should be used selectively and judiciously for appropriate clinical indications. Product monographs and other references should be consulted for detailed prescribing information[1-9].

A. BACKGROUND

1. General

In Canada, three antiviral medications are approved for the treatment and chemoprophylaxis of influenza: oseltamivir (Tamiflu[®]), zanamivir (Relenza[®]), and amantadine[1-4]. All require medical prescription. Oseltamivir and zanamivir are neuraminidase inhibitors; amantadine is an M2 ion channel inhibitor in the class of drugs known as adamantanes. Rimantadine is another adamantane approved in the United States but not approved for use in Canada. Oseltamivir and amantadine are oral medications whereas zanamivir is inhaled using a Diskhaler[®] device. Oseltamivir and zanamivir are options for both influenza A and B whereas amantadine is inherently ineffective against influenza B.

Until recently, **Oseltamivir** has been considered the preferred antiviral option for treatment or chemoprophylaxis of influenza among people one year of age and over. Oseltamivir is approved for treatment and post-exposure prophylaxis of influenza. It is also used off-label for pre-exposure prophylaxis in Canada[4]. In double-blind, placebo-controlled trials including children, young and elderly adults, the only adverse effect to occur significantly more often with oseltamivir compared to placebo was nausea or vomiting (2-17%) [7,10] These symptoms are generally mild, are mitigated by taking oseltamivir with food and cease on discontinuation of medication.

Zanamivir is an antiviral alternative to oseltamivir that is active against current influenza A/H1N1 (including oseltamivir-resistant viruses), A/H3N2, and influenza B. Zanamivir is approved in Canada for the treatment and chemoprophylaxis of people ≥ 7 years of age[4]. In the United States, zanamivir is approved for chemoprophylaxis indication as young as 5 years of age[5]. Zanamivir is approved for both post-exposure prophylaxis and for pre-exposure prophylaxis for up to 28 days duration in Canada; longer duration may also sometimes be warranted but would then be off-label[4]. Diskhaler[®] administration of zanamivir may be difficult in some groups such as the very old, young, or cognitively disabled[11]. No adverse effects have been significantly associated with zanamivir compared to placebo. There have been reports of bronchospasm in patients with underlying asthma/COPD taking zanamivir although clinical trials show no difference compared to placebo.

Amantadine is an antiviral alternative to oseltamivir that is active against current A/H1N1 strains but is no longer recommended for the treatment or prevention of influenza A/H3N2 due to high rates of amantadine resistance among circulating A/H3N2 viruses. Amantadine is not active against influenza B[4]. Careful dosing requirements apply to amantadine used in the elderly and those with renal conditions[6]. In otherwise healthy young adults given amantadine prophylactically, 5% to 10% report difficulty concentrating, insomnia, light-headedness, and irritability[6]. These side effects are usually mild and cease shortly after the prophylaxis is stopped; however, they occur more frequently in older populations unless a reduced dosage is used. Serious side effects (e.g. marked behavioural changes, delirium, hallucinations, agitation, seizures) have been associated with high plasma drug concentrations. These have been observed most often among those with renal insufficiency, seizure disorders, or certain psychiatric disorders, and among the elderly. Lower dosages for these people reduces the severity of such side effects[6].

2. Amantadine Resistance Patterns

During the 2007-08 season, 99% of the A/H3N2 isolates tested in Canada were resistant to amantadine whereas just 1% of the A/H1N1 isolates tested were amantadine resistant[4]. Since the start of the 2008-09 season (to February 5), the National Microbiology Laboratory (NML) has tested 72 influenza A isolates (40 A/H1N1 and 32 A/H3N2) for amantadine resistance. All of the A/H1N1 isolates were susceptible; however all of the A/H3N2 isolates were resistant to amantadine. The resistant isolates have come from Newfoundland, Quebec, Ontario, Saskatchewan, Alberta, British Columbia, and the Northwest Territories[12].

Resistance to amantadine emerges readily within days of starting treatment. Amantadine resistance is more likely to occur in semi-closed settings, such as within a family, facility, or institution (including nursing homes), where the drug is used for both prophylaxis and treatment, as opposed to prophylaxis alone. For this reason, simultaneous use of amantadine for prophylaxis and therapy within these settings is not advised. People in institutions treated with amantadine should be isolated from others until 2 days after treatment has ended. [6].

3. Neuraminidase Resistance Patterns

During the 2007-08 influenza season, oseltamivir resistance was first identified among circulating A/H1N1 viruses worldwide[4,13]. All oseltamivir-resistant strains were due to changes at position 274 in the viral neuraminidase gene (H274Y) – believed to be a spontaneous mutation conferring resistance[4,14]. The global proportion of oseltamivir-resistant A/H1N1 specimens among those tested increased from 16% during the northern hemisphere's 2007-08 season to 31% during the southern hemisphere's 2008 season[15]. In Canada, between August 26, 2007 and May 17, 2008, 481 influenza A/H1N1 isolates were tested for oseltamivir resistance by the NML and, of these, 125 (26%) were found to be resistant. All but one of the 125 oseltamivir resistant A/H1N1 viruses assessed in Canada during the 2007-08 season were sensitive to amantadine (>99%); the one virus isolate resistant to both oseltamivir and amantadine was from a person who was treated with both. Testing in the United States showed that all oseltamivir resistant A/H1N1 viruses assessed by the CDC for the 2007-08 season retained sensitivity to both zanamivir and amantadine[4,16].

During the 2008-09 season, to February 5, 2009, the NML has tested 146 influenza isolates (35 A/H1N1, 13 A/H3N2 & 98 B) for oseltamivir resistance[12]. All of the A/H3N2 and B isolates were sensitive to oseltamivir; however all of the thirty-five A/H1N1 isolates were resistant to oseltamivir due to the H274Y mutation. The thirty-five oseltamivir resistant A/H1N1 isolates came from Prince Edward Island, Nova Scotia, Ontario, Alberta, and British Columbia. All thirty-five A/H1N1 isolates that were oseltamivir-resistant were sensitive to amantadine. All 150 influenza isolates for the 2008-09 season to February 5 (39 A/H1N1, 13 A/H3N2 & 98 B) tested for zanamivir resistance have been found to be sensitive to zanamivir[9].

In addition, as of February 10, 2009, the **British Columbia** Centre for Disease Control (BCCDC) Virology laboratory has assessed 76 A/H1N1 viruses for the H274Y mutation denoting oseltamivir resistance using an innovative single nucleotide polymorphism (SNP) assay. Of these 76 A/H1N1 viruses assessed, 68 showed the oseltamivir resistance mutation (the other 8 are indeterminate and undergoing further characterization by sequence analysis of the neuraminidase gene)[12,17].

In the **United States** week 4 posting to FluView on February 6, 2009 indicates that, since October 1, 2008, 190 influenza A/H1N1, 41 influenza A/H3N2, and 77 influenza B viruses have been tested for antiviral resistance. Of the 190 A/H1N1 viruses assessed, 185 (97%) were oseltamivir-resistant, 2 (1%) were adamantane-resistant, and none was zanamivir-resistant. Of the 41 influenza A/H3N2 viruses assessed, all 41 were resistant to the adamantanes but all were sensitive to both oseltamivir and zanamivir[18].

In **Europe**, since week 40/2008 to February 4, 2009, of the 110 A/H1N1 virus isolates tested for resistance against neuraminidase inhibitors, 107 (97%) were oseltamivir-resistant, but all were sensitive to zanamivir and all of the 27 A/H1N1 viruses tested were sensitive to adamantanes. No antiviral resistance against neuraminidase inhibitors has been detected in the 138 A/H3N2 virus isolates tested so far this season in Europe. Of the 115 A/H3N2 isolates that were also tested for adamantane susceptibility, all 115 (100%) were resistant. All ten type B isolates tested were sensitive to both neuraminidase inhibitors [19].

B. INTERIM INFLUENZA ANTIVIRAL TREATMENT OPTIONS AS OF DECEMBER 28, 2008

Zanamivir, although difficult to use for some people, is active against all three human influenza types or subtypes (A/H3N2, A/H1N1, B). **Oseltamivir** is active against influenza A/H3N2 and B viruses but is not currently an effective option for A/H1N1 viruses. **Amantadine**, requiring dosage adjustment (most notably in the elderly and those with renal conditions) to minimize side effects, is active against A/H1N1 only.

Antivirals used for treatment of influenza are most beneficial when started within the first two days of illness. The effectiveness of antiviral options in reducing the duration and/or complications of influenza has been summarized in published reviews[7,8,20-25]. Data for safety and effectiveness are lacking for children less than one year of age. Treatment effectiveness data are not available for all antiviral options in all age or at-risk groups for all outcomes; more systematic evaluation is needed especially related to the benefit against serious outcomes for zanamivir and amantadine as antiviral alternatives. In the meantime, antivirals should be used selectively and judiciously for appropriate clinical indications, most notably for individuals with severe illness and those most likely to develop complications or die as a result of influenza[7].

Position papers of the Canadian Paediatric Society and Association of Medical Microbiology and Infectious Diseases (AMMI) Canada (<http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=18382639>) and the American Pediatric Society (<http://aappolicy.aappublications.org/cgi/reprint/pediatrics;119/4/852.pdf>) are readily available and valuable sources of information concerning influenza antivirals.

Choice of antiviral should be based on the type/sub-type of influenza (if known), predominant viruses circulating in the community, patient age and underlying health, anticipated antiviral benefits and adverse effects, ease of administration, contraindications/warnings/precautions and, ultimately, clinician judgment. Clinicians should consult package inserts and references for specific antiviral prescribing information[1-9].

C. DECIDING ON INFLUENZA ANTIVIRAL OPTIONS BASED ON SURVEILLANCE & TESTING

Health care providers considering influenza antivirals in the treatment of patients should take into account the following for the 2008-09 season (current to February 10, 2009):

- 1) **Vaccination** is the primary prevention strategy for influenza. In particular, note that the A/H1N1 component of the 2008-09 vaccine is a good antigenic match to current oseltamivir resistant A/H1N1 viruses. Pneumococcal vaccine for eligible persons will help prevent secondary complications. Cough etiquette, hand hygiene and limiting contact with others when ill, reduces respiratory virus transmission.
- 2) **Surveillance** for influenza antiviral resistance is ongoing in Canada. Clinicians should regularly review public health updates to determine the likelihood of type (A or B) or subtype-specific (A/H1N1, A/H3N2) influenza illness in their area. In BC, provincial influenza surveillance results are regularly updated and posted throughout the influenza season (<http://www.bccdc.org/content.php?item=35>) [17]. National profiles are posted at the FluWatch website (<http://www.phac-aspc.gc.ca/fluwatch/>) [12]. Clinicians should be alert for changes relevant to antiviral options throughout the season and consult public health as needed.
- 3) **Diagnostic test results**, and their availability, detail and timeliness:
 - a. **No influenza test results available (Figure A).**
 - b. **Rapid antigen, near patient or point-of-care (POC) testing (Figure B).**
 - i. Some rapid tests can distinguish between influenza A and B but do not provide subtype (A/H3N2 versus A/H1N1) detail. These tests can take 15 minutes to 2 hours and some can be used in the office setting.
 - ii. In general, the sensitivity of rapid tests is variable (median 70–75%) and lower than that of cell culture. Their median specificity is 90–95%. Test parameters may vary with age and other considerations.
 - iii. Because of concern related to false negative and false positive results (depending upon the stage of the season), diagnosis by rapid POC tests must be interpreted with caution and where indicated should be confirmed by direct immunofluorescence microscopy (DFA), cell culture or RT-PCR testing. Complete details regarding World Health Organization and CDC recommendations on the use of rapid influenza testing, including a review of kits, can be found at the websites in references [26,27].
 - c. **Laboratory confirmation with a diagnostic test capable of distinguishing influenza A/H1N1 versus A/H3N2 or B viruses with results available in a timely way (Figure C).**
 - i. Local availability/timeliness, either routinely or at special request, should be explored by interested clinicians.
- 4) **Chemoprophylaxis** may be warranted in some people [1-9]. Choice of antiviral should similarly be guided by the above considerations. Facility guidelines for institutional outbreak control have been separately provided to local public health authorities. Consult local public health as needed.

Figure A: No Influenza Test Results Available but Clinical Suspicion of Influenza and Indication for Treatment are Strong¹





Figure B^b: Rapid Point of Care Test Results for Influenza A or B Available but Subtype Results Not Available and Strong Indication for Treatment¹




¹Antivirals used for influenza treatment are most beneficial when started within the first two days of illness. Antivirals should be used selectively and judiciously for appropriate clinical indications, most notably for individuals with severe illness and those most likely to develop complications or die as a result of influenza. See narrative section B of these guidelines and consult specific antiviral package insert and/or references for prescribing detail including dose/indications/contraindications/precautions/warnings.

²Surveillance data may be driven by younger age groups. Circulating A/H1N1 may be more likely to cause classic influenza illness and/or be reported in younger compared to elderly people and this requires consideration in treatment choice.

³Data for safety and effectiveness are lacking for children < 1 year of age and no influenza antivirals are yet approved for use in that very young age group. Expert infectious disease consultation is advised in considering pediatric antiviral treatment options, especially for hospitalized children or those with severe illness.

⁴Combined therapy with (amantadine plus oseltamivir) will address A/H1N1 (amantadine), A/H3N2 (oseltamivir) and B (oseltamivir), if multiple influenza types/subtype may be circulating. Human data are lacking to support the benefits of combination antiviral treatment of influenza; however, these interim recommendations are intended to assist clinicians treating patients who might be infected with oseltamivir-resistant influenza A/H1N1 virus when individual subtype-specific laboratory confirmation is lacking.

^bSee Narrative in Section C3b of these guidelines related to rapid antigen, point of care tests. If there is strong clinical suspicion of influenza and strong indication for treatment and the rapid test is negative, consider treatment options per Figure A above.



^{c1} Antivirals used for influenza treatment are most beneficial when started within the first two days of illness. Antivirals should be used selectively and judiciously for appropriate clinical indications, most notably for individuals with severe illness and those most likely to develop complications or die as a result of influenza. See narrative section B of these guidelines and consult specific antiviral package insert and/or references for prescribing detail including dose/indications/contraindications/precautions/warnings.

^{c2} When submitting a specimen for laboratory testing to a Virology laboratory, there will be added transportation and processing time and subtype or oseltamivir resistance results may not be routinely available/reported or provided in a timely way to guide clinical decision-making. Antiviral treatment options are time-sensitive. Local availability and timeliness of such diagnostic testing, either routinely or at special request, should be explored by interested clinicians. In such cases, treatment options can be considered per Figure A or B and revised with the availability of test results if clinically warranted.

In British Columbia, the Virology Laboratory of the BC Centre for Disease Control is able to conduct subtyping of influenza viruses for special surveillance indications and clinically upon request. If the respiratory specimen arrives before 14:00 Monday to Friday or before 10 AM on Saturday, subtype results could be made available the next business day following identification of influenza by the BCCDC laboratory, if specially requested. Clinicians requesting this detail for individual patients are required to notify the BCCDC laboratory in advance of specimen submission.

^{c3} Data for safety and effectiveness are lacking for children < 1 year of age and no influenza antivirals are yet approved for use in that very young age group. Expert infectious disease consultation is advised in considering pediatric antiviral treatment options, especially for hospitalized children or those with severe illness.

D. REFERENCES

- 1) Oseltamivir product monograph: <http://205.193.93.51/dpdonline/displayInfo.do?drugCode=Bu0t42pnyOU%3D>
- 2) Zanamivir product monograph: <http://205.193.93.51/dpdonline/displayInfo.do?drugCode=9aEKAhmK08%3D>
- 3) Amantadine product monograph (Pharmel, 2004): <http://205.193.93.51/dpdonline/displayInfo.do?drugCode=kg7XzgefXiQ%3D>
- 4) Statement on influenza vaccination for the 2008-2009 season. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2008 Jul 15;34(ACS-3):1-46. Available at: <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/08pdf/acs-3.pdf>
- 5) Antiviral agents for seasonal influenza: dosage. CDC, Atlanta, US. <http://www.cdc.gov/flu/professionals/antivirals/dosage.htm>
- 6) Statement on influenza vaccination for the 2005-2006 season. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2006 Jun 15; 31(ACS-6): 1-32. Available at: <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05pdf/acs-dcc3106.pdf>
- 7) Allen UD, Aoki F, Stiver HG et al. *The use of antiviral drugs for influenza: Recommended guidelines for practitioners*. Can J Infect Dis Med Microbiol 2006;17:273-79. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=18382639>
- 8) American Academy of Pediatrics Committee on Infectious Diseases. Antiviral therapy and prophylaxis for influenza in children. Pediatrics 2007;119:852-860. Available at: <http://aappolicy.aappublications.org/cgi/reprint/pediatrics;119/4/852.pdf>
- 9) Interim Recommendations for the Use of Influenza Antiviral Medications in the Setting of Oseltamivir Resistance among Circulating Influenza A (H1N1) Viruses, 2008-09 Influenza Season. Available at: <http://www.cdc.gov/flu/professionals/antivirals/index.htm>
- 10) Dutkowski R, Thakrar B, Froehlich E et al. Safety and pharmacology of oseltamivir in clinical use. Drug Safety 2003;26:787-801.
- 11) Lee C, Loeb M, Phillips A, Nesbitt J, Smith K, Fearon M, McArthur MA, Mazzulli T, Li Y, McGeer A. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol. 2000 Nov;21(11):700-4. available at: <http://www.journals.uchicago.edu/doi/pdf/10.1086/501727>
- 12) Canada's Influenza "FluWatch" weekly report available at: <http://www.phac-aspc.gc.ca/fluwatch/>
- 13) Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro.Surveill 2008;13.
- 14) Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 2008 Jul 25;4(7):e1000103.
- 15) World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir - 2008 influenza season, southern hemisphere. Available at: <http://www.who.int/csr/disease/influenza/H1N1200801013.pdf>
- 16) 2007-08 U.S. Influenza Season Summary. CDC, Atlanta. Available at: <http://www.cdc.gov/flu/weekly/weeklyarchives2007-2008/07-08summary.htm>
- 17) BC Influenza Surveillance Updates. Available at: <http://www.bccdc.org/content.php?item=35>
- 18) FluView – A weekly influenza surveillance report prepared by the influenza division, CDC, Atlanta US: <http://www.cdc.gov/flu/weekly/>
- 19) European Influenza Surveillance Scheme (EISS) Weekly Bulletin: http://www.eiss.org/cgi-files/bulletin_v2.cgi?season=2008
- 20) Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJL. Amantadine and rimantadine for influenza A in children and the elderly. *Cochrane Database of Systematic Reviews* 2008, Issue 1. Art. No.: CD002745. DOI: 10.1002/14651858.CD002745.pub2.
- 21) Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. *Cochrane Database Syst Rev*. 2006 Apr 19;(2):CD001169. Review.
- 22) Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. *Lancet* 2006; 367: 303-313.
- 23) Matheson NJ, Harnden A, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. *Cochrane Database of Systematic Reviews* 2007, Issue 1. Art. No.: CD002744. DOI: 10.1002/14651858.CD002744.pub2.
- 24) Jefferson T, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. *Cochrane Database of Systematic Reviews* 2008, Issue 4. DOI: 10.1002/14651858.CD001265.pub2
- 25) Ambrozaitis A, Gravenstein S, van Essen GA, Rubinstein E, Balciuniene L, Stikleryte A, Crawford C, Elliott M, Shult P. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. *J Am Med Dir Assoc*. 2005 Nov-Dec;6(6):367-74.
- 26) WHO recommendations on the use of rapid testing for influenza diagnosis. Available at: http://www.who.int/csr/disease/avian_influenza/guidelines/rapid_testing/en/index.html
- 27) Rapid diagnostic testing for influenza – information for health care professionals. CDC, Atlanta. Available at: <http://www.cdc.gov/flu/professionals/diagnosis/rapidclin.htm>